Tuberculosis Clinical Trial
Official title:
A Phase II, Open-label Trial With TMC207 as Part of a Multi-drug Resistant Tuberculosis (MDR-TB) Treatment Regimen in Subjects With Sputum Smear-positive Pulmonary Infection With MDR-TB.
The purpose of this study is to evaluate the safety, tolerability and effectiveness of TMC207 in combination with an individualized background regimen (BR) of antibacterial drugs as treatment for MDR-TB
This is a Phase II, open-label (all people involved know the identity of the intervention)
trial to evaluate the safety, tolerability, and efficacy of TMC207 as part of an
individualized Multi-drug Resistant Tuberculosis (MDR-TB) treatment regimen in participants
with sputum smear-positive pulmonary MDR-TB. Approximately 225 participants will receive
TMC207 for 24 weeks in combination with an individualized background regimen (BR) of
antibacterial drugs used in the treatment of TB according to national and international
guidelines and selected at the baseline visit. TMC207 dosage will be 400 mg once daily
(q.d.) for the first 2 weeks and 200 mg 3 times/week (t.i.w.) for the following 22 weeks.
Upon completion of the 24-week treatment with TMC207, all participants will continue to
receive their BR under the care of their physician and in accordance with national TB
program (NTP) treatment guidelines.
Additionally, the pharmacokinetics (how the body absorbs, distributes, metabolizes and
eliminates a drug) of TMC207 and its N-monodesmethyl metabolite (M2), and
pharmacokinetic/pharmacodynamic (the study of the action or effects a drug has on the body)
relationships for safety and efficacy will be assessed. Safety evaluations that will be
performed are lab tests, vital signs, ECG, reporting of adverse events, physical
examinations and X-rays.
All participants will be followed up for 19 months after their last intake of TMC207. Also
participants who prematurely withdraw (unless they withdraw consent) will be followed for
this period or until the last follow-up visit for the last patient in the trial.
Investigators will be asked to provide information about the survival/clinical outcome of
these participants throughout the follow-up period, approximately every 6 months.
Primary outcome is time to sputum culture conversion in Mycobacteria Growth Indicator Tube
(MGIT) during and beyond treatment with TMC207. Sputum culture conversion will be defined as
2 consecutive negative cultures from sputa collected at least 28 days apart.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05738681 -
Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial
|
Phase 2/Phase 3 | |
Recruiting |
NCT05526885 -
Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined With a CRP Triage Test, Both Followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa
|
N/A | |
Completed |
NCT04369326 -
Community Initiated Preventive Therapy for TB
|
N/A | |
Recruiting |
NCT04568967 -
TB-CAPT EXULTANT - HIV
|
N/A | |
Completed |
NCT02337270 -
Phase 1 Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol
|
Phase 1 | |
Not yet recruiting |
NCT06253715 -
Shortened Regimen for Drug-susceptible TB in Children
|
Phase 3 | |
Recruiting |
NCT04271397 -
Immunological Biomarkers in Tuberculosis Management
|
N/A | |
Withdrawn |
NCT03639038 -
Tuberculosis Diagnosis by Flow Cytometry
|
||
Completed |
NCT03199313 -
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid
|
Phase 1 | |
Recruiting |
NCT04975178 -
Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa
|
Phase 3 | |
Completed |
NCT04463680 -
Rifampin and the Contraceptive Implant
|
Phase 4 | |
Completed |
NCT03973970 -
Assessing the Ability of the T-SPOT®.TB Test (IQ)
|
||
Recruiting |
NCT04230395 -
Alcohol Reduction Among People With TB and HIV in India
|
N/A | |
Completed |
NCT04874948 -
Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment
|
Phase 1 | |
Active, not recruiting |
NCT02906007 -
Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05917210 -
Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda
|
N/A | |
Not yet recruiting |
NCT06017843 -
Impact Evaluation of Use of MATCH AI Predictive Modelling for Identification of Hotspots for TB Active Case Finding
|
N/A | |
Not yet recruiting |
NCT05845112 -
Start Taking Action For TB Diagnosis
|
||
Active, not recruiting |
NCT02715271 -
Study of TB Lesions Obtained in Therapeutical Surgery
|
||
Completed |
NCT02781909 -
Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis
|
Phase 2 |